🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What a master class in Apo(a) by Michael Boffa! It's so hard to summarize in a tweet Really interesting data showing how specific mutations on His33 play a major role in OxPL. National Lipid Association #NLASessions

A rare picture of Lp(a)! Here, Michael Boffa shows us the thin, fiber-like Apo(a) amino terminus (the "tail") in Cryo-ET! Its variability and mobility make it challenging to get high-resolution 3D reconstruction #NLASessions National Lipid Association

When it rains, it pours - More OBI data. Across 3 phase 3 trials, BROADWAY (obi), BROOKLYN (obi) & TANDEM (obi + ezetimibe), obicetrapib, an oral CETP inhibitor, effectively reduced not only LDL-C, but also Lp(a), especially in those with moderately elevated Lp(a) levels. In

Today at #NLASessions ! Back to back lectures from the best on the field! Great sessions about risk stratification coming up! National Lipid Association

Does HDL-C matter? Anand Rhotagi: Despite low HLD-C being a good predictor of ASCVD, there's been a failure on risk reduction of therapeutics rising HDL-C #NLASessions National Lipid Association #HDL

Key takeaways from HDL and Diabetes😮 -Diabetes associated changes in HDL are more associated with the U-shaped relationship. This can be largely associated with the particle size shift National Lipid Association Anand Rohatgi #NLASessions

Take-home message from Anand Rohatgi masterclass! ✉️ HDL are heterogeneous particles, such that cholesterol content does not equal particle concentration or functionality! Measuring functionality or composition for ASVD or Rx remains complicated #NLASessions National Lipid Association

If the hypercholesterolemia is not #FH, what is it? Dan Soffer solves this riddle! For this, we should always think about lipids-pheno-clinic-genetic perspective! National Lipid Association #NLASessions

Really enjoyed Max Petersen’s talk at #NLASessions on the topic of hypothetical mechanisms of increased LDL cholesterol and ApoB with ketogenic diets. Looking forward to his forthcoming data measuring metabolic fluxes! clinicaltrials.gov/study/NCT06894…

Fantastic talk by Dr. Ira Goldberg on triglycerides and CVD 👏 Key takeaways: ➡️ Hypertriglyceridemia can increase CVD risk via LPL pathway ➡️ Post-prandial lipemia is an independent risk factor for CVD ➡️ All TRLs are likely atherogenic #NLASessions National Lipid Association

Mi imagen fue usada sin mi autorizacion en un anuncio de un producto que carece de sustento cientifico. Los agonistas GLP1 no pueden ser administrados por via transdermica. Eviten caer en engaños

Curso avanzado de dislipemias raras o poco frecuentes European Atherosclerosis Society Sociedad Argentina Lípidos (SAL) Pablo Corral MD 🗓️miercoles 11 de junio ✏️ us02web.zoom.us/webinar/regist…

As always, my pal, Pablo Corral MD alerts us to crucial articles which help us to be aware of and to slay causal ASCVD risk factors like apoB and LDL-P. National Lipid Association European Atherosclerosis Society ASPC European Society of Cardiology International Atherosclerosis Society (IAS) #cholesterol

📌 #LDL-C is not the whole story. 🔬 #ApoB-100 shape—not just quantity—may drive plaque risk 🧱 Particle retention 🧬 Aggregation in arterial wall 🔜 We may treat how apoB behaves, not just how much there is 📄 Curr Opin Lipidol 2025 🔗 doi.org/10.1097/MOL.00… #EndoTwitter

If you missed any of the amazing lectures from Thomas Dayspring, no worries! Here are the recordings! Each one is worth every second!

Excited to see from the NIH team this new modified Sampson equation for a more accurate determination of LDLC. It surpasses all other calculations (Original Sampson, Martin Hopkins, Friedewald) & has high correlation with the gold standard ultracentrifugation method -

🔰Función endotelial en pacientes de alto riesgo con ezetimiba. En este estudio de 91 pacientes se encontró que: ✅La función endotelial es mejor en pacientes de alto riesgo con ECVA preexistente tratados con ezetimiba junto con estatinas que en pacientes con estatinas en

🔰Una ecuación de Sampson-NIH modificada con mayor precisión para estimar niveles bajos de C-LDL. 👏Que gran trabajo de Rafael Zubirán y sus colegas, utilizando los resultados de las pruebas del panel lipídico de la Clínica Mayo y el ensayo clínico FOURIER, realizaron una ecuación

Even #HappyGilmore2 knows!